Bortezomib and extramedullary disease in multiple myeloma: The shine and dark side of the moon

Simple item page
dc.contributor.buuauthorAli, Rıdvan
dc.contributor.buuauthorÖzkalemkaş, Fahir
dc.contributor.buuauthorÖzkan, Atilla
dc.contributor.buuauthorÖzkocaman, Vildan
dc.contributor.buuauthorÖzçelik, Tülay
dc.contributor.buuauthorOzan, Ülkü
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkoloji Anabilim Dalı.tr_TR
dc.contributor.researcheridAAG-8495-2021tr_TR
dc.contributor.researcheridAAH-1854-2021tr_TR
dc.contributor.scopusid7201813027tr_TR
dc.contributor.scopusid6601912387tr_TR
dc.contributor.scopusid9250698600tr_TR
dc.contributor.scopusid6603145040tr_TR
dc.contributor.scopusid7005424333tr_TR
dc.contributor.scopusid6507254632tr_TR
dc.contributor.scopusid8843050600tr_TR
dc.contributor.scopusid6602797853tr_TR
dc.date.accessioned2022-10-06T07:43:36Z
dc.date.available2022-10-06T07:43:36Z
dc.date.issued2007-08
dc.identifier.citationAli, R. vd. (2007). "Bortezomib and extramedullary disease in multiple myeloma: The shine and dark side of the moon". Lekukemia Research, 31(8), 1153-1155.en_US
dc.identifier.endpage1153tr_TR
dc.identifier.issn0145-2126
dc.identifier.issn1873-5835
dc.identifier.issue8tr_TR
dc.identifier.pubmed16945413tr_TR
dc.identifier.scopus2-s2.0-34249871670tr_TR
dc.identifier.urihttps://doi.org/10.1016/j.leukres.2006.07.017
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0145212606002700
dc.identifier.urihttp://hdl.handle.net/11452/28992
dc.identifier.volume31tr_TR
dc.identifier.wos000248062000019tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Scienceen_US
dc.relation.journalLeukemia Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.relation.tubitak1155tr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectProgressionen_US
dc.subjectPlasmacytomaen_US
dc.subjectTherapyen_US
dc.subject.emtreeDisease courseen_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeAllogeneic stem cell transplantationen_US
dc.subject.emtreeAutologous stem cell transplantationen_US
dc.subject.emtreeBackacheen_US
dc.subject.emtreeBone marrow biopsyen_US
dc.subject.emtreeCancer relapseen_US
dc.subject.emtreeCancer stagingen_US
dc.subject.emtreeCase reporten_US
dc.subject.emtreeCombination chemotherapyen_US
dc.subject.emtreeComputer assisted tomographyen_US
dc.subject.emtreeDiarrheaen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeAntineoplastic agenten_US
dc.subject.emtreeHistopathologyen_US
dc.subject.emtreePrednisoneen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeVincristineen_US
dc.subject.emtreeBoronic acid derivativeen_US
dc.subject.emtreeBortezomiben_US
dc.subject.emtreeHuman tissueen_US
dc.subject.emtreePyrazine derivativeen_US
dc.subject.emtreeLetteren_US
dc.subject.emtreeAlpha2b interferonen_US
dc.subject.emtreePlasmacytomaen_US
dc.subject.emtreeBortezomiben_US
dc.subject.emtreeMultiple cycle treatmenten_US
dc.subject.emtreeMultiple myelomaen_US
dc.subject.emtreeNeuropathyen_US
dc.subject.emtreeNeutropeniaen_US
dc.subject.emtreePathologyen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeDexamethasoneen_US
dc.subject.emtreePneumoniaen_US
dc.subject.emtreePlasmacytomaen_US
dc.subject.emtreeDoxorubicinen_US
dc.subject.emtreeMelphalanen_US
dc.subject.emtreeRadiodiagnosisen_US
dc.subject.emtreeRemissionen_US
dc.subject.emtreeThrombocytopeniaen_US
dc.subject.emtreeTreatment outcomeen_US
dc.subject.emtreeMultiple myelomaen_US
dc.subject.meshPlasmacytomaen_US
dc.subject.meshAgeden_US
dc.subject.meshAntineoplastic agentsen_US
dc.subject.meshBoronic acidsen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMultiple myelomaen_US
dc.subject.meshPyrazinesen_US
dc.subject.meshTreatment outcomeen_US
dc.subject.scopusPlasmacytoma; Multiple Myeloma; Pleura Effusionen_US
dc.subject.wosOncologyen_US
dc.subject.wosHematologyen_US
dc.titleBortezomib and extramedullary disease in multiple myeloma: The shine and dark side of the moonen_US
dc.typeLetter
dc.wos.quartileQ2 (Hematology)en_US
dc.wos.quartileQ3 (Oncology)en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
PubMed
Scopus